Eligibility

• Inclusion criteria: Participants must be age 18 or greater and meet criteria for either Alzheimer's disease (AD), behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SD), primary progressive aphasia (PPA), FTD with amyotrophic lateral sclerosis (FTD-ALS), corticobasal degeneration (CBD), Creutzfeldt-Jakob disease (CJD), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), other rapidly progressive dementia, mild cognitive impairment (MCI) or healthy volunteer. Participants will need a reliable study partner who has frequent contact with the participant, is available to provide information about the participant, and who can accompany the participant to research visits as needed. Participants must be willing and able to have brain MRIs through the course of the study and have a Mini Mental State Exam (MMSE) score of 15 or greater AND/OR a CDR less than 2 at time of screening. Anyone not meeting these criteria will need to be approved by the Study Director.
• Exclusion criteria: A history of Korsakoff encephalopathy, alcohol abuse or dependence within 5 years of the onset of dementia, substance abuse, head trauma with persistent deficits and a loss of consciousness greater than 30 minutes, CNS lesions deemed to be clinically significant, epilepsy or seizure disorder not due to correctable metabolic abnormality, hydrocephalus, intracerebral hemorrhage, ischemic vascular dementia (VaD), multisystem atrophy, multiple sclerosis or other demyelinating disease, encephalitis or meningitis, untreated B12 deficiency, untreated hypothyroidism, untreated syphilis, positive HIV status, renal insufficiency requiring dialysis, symptomatic liver disease, anxiety disorder (not due to dementia and requiring medication more than 3 times per week), severe periventricular white matter disease or greater than grade 4 white matter lesions, lacunar infarcts deemed to be clinically significant, cortical stroke, respiratory condition requiring oxygen, or significant systemic medical illness such as cancer requiring chemotherapy or end stage cardiac insufficiency, pacemaker, ferromagnetic material (in soft tissue), benzodiazepines (no triazolam, but other short-acting benzodiazepines are OK), antidepressant therapy with amitriptyline or doxepine or treatment not stable during past year, lithium, neuroleptics in the phenothiazine and haloperidol families (atypicals OK), narcotics (codeine is OK, but hold 24 hours before neuropsychological testing), anticonvulsants outside of therapeutic ranges, antihistamines (more than 3 times per week; cannot be taken 24 hours before neuropsychological testing).

article_image_comp: